Wrazliwosc na worikonazol grzybow izolowanych z materialu klinicznego

• Autorzy: Pawlik B. , Szul A. , Macura A.B.

Warianty tytułu

EN

Susceptibility of fungi isolated from clinical materials to Voriconazole

• Języki publikacji: PL

Abstrakty

PL

Oceniono in vitro skuteczność worikonazolu wobec grzybów drożdżopodob- nych, pleśniowych i dermatofitów. Lek wykazał się znaczną skutecznością wobec innych niż C. albicans gatunków z rodzaju Candida, grzybów pleśniowych z rodzaju Aspergillus, Fusarium i Alternaria, często wywołujących u ludzi zakażenia i uczulenia oraz wobec dermatofitów z gatunków Trichophyton mentagrophytes i T. rubrum, najczęściej wywołujących dermatomykozy w Polsce.

EN

The objective of the study was evaluation of the susceptibility of 139 fungal strains isolated from clinical materials to Voriconazole, a new antifungal agent of the triazole group. A dilution method was used. The drug was incorporated into the culture medium at concentrations 0.1-100 mg/l. It was found out that the antifungal effectiveness of the drug varied both between various fungal genera and species, and between strains within the same species. Total inhibition of the growth of 20 % of the yeast-like fungi and 23.3% of the moulds was achieved at concentration 0.1 mg/l. It was documented that the species Candida guilliermondii, C. kefyr, Saccharomyces cerevisiae and Aspergillus fumigains, that as a rule are resistant to triazoles, were highly susceptible to Voriconazole. Dermatophytes, too, were highly susceptible to the drug, particularly Trichophyton mentagrophytes and T. rubrum. The drug at concentration 0.1 mg/l totally inhibited 73.5% of the dermatophytes, and at concentration 1 mg/l - 97,0% of them after 7 day incubation. After 14 day incubation, 97,0% of the strains were also inhibited at drug concentration not exceeding 1 mg/l.

Słowa kluczowe

PL

grzyby drozdzopodobne; dermatofity; plesnie; Candida; Aspergillus; Fusarium; Alternaria; choroby czlowieka; dermatomykoza; leczenie; wrazliwosc na leki; worykonazol

• Wydawca: -
• Czasopismo: Medycyna Doświadczalna i Mikrobiologia
• Rocznik: 2006
• Tom: 58
• Numer: 2
• Opis fizyczny: s.155-161,tab.,bibliogr.

Twórcy

autor

Pawlik B.

• Collegium Medicum Uniwersytetu Jagiellonskiego w Krakowie, ul.Czysta 18, 31-121 Krakow

autor

Szul A.

autor

Macura A.B.

Bibliografia

• 1. Ally R, Schumann D, Kreisel W i inni. A randomized double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of oesophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001; 33: 1447-54.
• 2. Bigley WH, Duarte RF, Gisling RD i inni. Fusarium dimerum infection in stem cell transplant treated succesfully with voriconazole. Bone Marrow Transplant 2004; 34: 815-7.
• 3. Cttenca-Estrella M, Rodriguez-Tudela JL, Mellado E i inni. Comparison of the in vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin В against clinical isolates of Aspergillus fumigatus. JAntimicrob Chemother 1988; 42:531-3.
• 4. Denning DW, Ribaud P, Milpied N i inni. Efficacy and safety of voriconazole in thetreatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563-71.
• 5. Gomez-Lopez A, Garcia-Effron G, Mellado E i inni. In vitro activities of three licensed antifungal agents against Spanish clinical isolates oî Aspergillus sp. Antimicrob Agents Chemother 2003; 47: 3085-8.
• 6. Hazen KC, Baron EJ, Colombo AL. i inni. Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole і a 4-year global evaluation using disk diffusion. J Clin Microbiol 2003; 41: 5623-32.
• 7. Herbrecht R, Denning DW, Patterson TF i inni. Voriconazole versus amphotericin В for primary therapy of onvasive aspergillosis. N Engl J Med 2002; 347: 408-15.
• 8. Pawlik В, Macura AB. Diagnostyka laboratoryjna w mikologii. W: Zarys mikologii lekarskiej. Red. E. Baran, Volumed, Wrocław, 1998, 541-72.
• 9. Perfect JR, Man KA, Waish TJ i inni. Voriconazole treatment for less-common, emerging or refractory fungal infections. Clin Infect Dis 2003; 36: 1122-31.
• 10. Pfaller MA, Diekema DJ, Messer S.A. i inni. In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida Species infrequently isolated from blood. J Clin Microbiol 2003; 41: 78-83.
• 11. Serrano-Martino M, Chavez-Caballero M, íalverde-Conde A i inni. Actividad in vitro de voriconazol y otros tres antifungicos frente a dermatofitos. Enferm Infecc Microbiol Clin 2003; 21: 484-7.
• 12. Vant-Hek LG, Verweij PE, Weemans CM i inni. Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease. Am J Respir Dri Care Med 1998; 157: 1694-6.
• 13. Walsh TJ, Karlsson MO, Driscoll T i inni. Pharmacokinetics and safety of intra venous voriconazole in children after single- or multipledose administration. Antimicrob Agens Chemother 2004; 48: 2166-72.
• 14. Walsh TJ, Pappas P, Winston DJ i inni. Voriconazole compared with liposomal amphotericin В for empirical therapy in patients with neutropenia. N Eng J Med 2002; 346: 225-34.